News
-
-
PRESS RELEASE
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
Jaguar Health's crofelemer granted Orphan Drug Designation by FDA and EMA for MVID and SBS. Clinical trials submitted in Italy and Germany for SBS and MVID treatment. Jaguar focuses on plant-based medicines for gastrointestinal distress -
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Jaguar Health, Inc. to conduct an investor webcast on May 14, 2024, to review first-quarter financials and provide corporate updates. Company plans to file its Earnings Report on the same day -
-
PRESS RELEASE
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Jaguar Health, Inc. establishes Investigational New Animal Drug (INAD) file with FDA for crofelemer to treat canine diarrhea. Conditional approval received for chemotherapy-induced diarrhea (CID) in dogs -
-
PRESS RELEASE
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's plant-based drug crofelemer granted Orphan Drug Designation for MVID and SBS, with proof-of-concept studies planned for 2024. Napo sponsors Elite Ped-GI Congress panel discussion on rare digestive disorders -
-
